Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H ( (HK:2252) ) has shared an update.
Shanghai MicroPort MedBot (Group) Co., Ltd. has scheduled a board meeting for 26 March 2026 to review and approve the audited financial results for the year ended 31 December 2025 and to authorize their release. The board will also consider whether to recommend a final dividend and address other corporate matters, a step that signals the upcoming disclosure of the group’s annual performance and potential shareholder returns.
The meeting date gives investors a timeline for when to expect key financial information that could influence market perception of the medtech company’s growth trajectory. Any decision on a final dividend will be closely watched as an indicator of the group’s cash position, capital allocation priorities, and confidence in its operating outlook.
The most recent analyst rating on (HK:2252) stock is a Buy with a HK$33.00 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.
More about Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
Shanghai MicroPort MedBot (Group) Co., Ltd. is a China-based medical technology company focused on robotic and intelligent surgical systems and related medtech solutions. Listed in Hong Kong, the group operates through multiple subsidiaries to develop and commercialize advanced surgical platforms for hospitals and healthcare providers in domestic and international markets.
Average Trading Volume: 8,014,137
Technical Sentiment Signal: Buy
Current Market Cap: HK$24.67B
Learn more about 2252 stock on TipRanks’ Stock Analysis page.